ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KYMR Kymera Therapeutics Inc

33.97
-1.15 (-3.27%)
20 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Kymera Therapeutics Inc KYMR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-1.15 -3.27% 33.97 06:25:01
Open Price Low Price High Price Close Price Previous Close
34.98 33.35 35.53 33.97 35.12
more quote information »

Recent News

Date Time Source Heading
08/4/202421:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
09/3/202402:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
05/3/202410:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202410:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202410:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202409:50EDGAR2Form 144 - Report of proposed sale of securities
05/3/202409:47EDGAR2Form 144 - Report of proposed sale of securities
28/2/202423:00GLOBEKymera Therapeutics to Participate in Upcoming March..
28/2/202408:22EDGAR2Form 144 - Report of proposed sale of securities
22/2/202423:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202423:10EDGAR2Form 8-K - Current report
22/2/202423:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
15/2/202423:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
10/2/202411:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/2/202408:22EDGAR2Form 144 - Report of proposed sale of securities
31/1/202423:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
10/1/202401:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
10/1/202401:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
06/1/202408:11EDGAR2Form 8-K - Current report
06/1/202408:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202422:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
05/1/202408:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202408:01GLOBEKymera Therapeutics Announces Proposed Public Offering
04/1/202423:08EDGAR2Form 8-K - Current report
04/1/202423:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
03/1/202409:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202423:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
13/12/202323:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
11/12/202313:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
07/12/202323:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
14/11/202303:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
07/11/202310:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202300:15EDGAR2Form 8-K - Current report
03/11/202300:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
02/11/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202322:10EDGAR2Form 8-K - Current report
02/11/202322:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
01/11/202322:00GLOBEKymera Therapeutics to Participate in Upcoming November..
27/10/202322:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
26/10/202322:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..
16/10/202322:00GLOBEKymera Therapeutics Presents Preclinical Data Demonstrating..
18/9/202321:00GLOBEKymera Therapeutics Receives U.S. FDA Fast Track Designation..
09/8/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202321:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202321:10EDGAR2Form 8-K - Current report
03/8/202321:00GLOBEKymera Therapeutics Announces Second Quarter 2023 Financial..
27/7/202321:00GLOBEKymera Therapeutics to Report Second Quarter 2023 Financial..
22/6/202323:21DJNKymera Therapeutics Gets Orphan-Drug Status for Leukemia..
22/6/202322:30GLOBEKymera Therapeutics Receives FDA Orphan Drug Designation for..
14/6/202316:30GLOBEKymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD..

Your Recent History

Delayed Upgrade Clock